

Patent Application
Attorney Docket No. PC10959AGPR

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to: Hon. Director - U.S. Patent and Trademark Office, Washington, D.C. 20231 on this 22nd day of March, 2002.

By

(Signature of person mailing)

Janice Denison

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Mark David Fidock :

APPLICATION NO.: 10/023,775

: Examiner: To be assigned

FILING DATE: December 18, 2001

: Group Art Unit: 1642

TITLE: Novel Polypeptide :

Director - U.S. Patent and Trademark Office
Washington, D.C. 20231

NOTIFICATION AND REQUEST FOR CLARIFICATION

Dear Sir:

Applicant recently received the Filing Receipt as well as a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. Copies of each are enclosed, along with attachments thereto as received by Applicant. In reviewing the Raw Sequence Listing Error Report to ascertain what insufficiencies existed in Applicant's Sequence Listing and Diskette, it was noted that the Raw Sequence Listing did not consist of sequence information from Applicant's application. It appears that the sequence listing analyzed in this report is connected to an application made by Boehringer Mannheim GmbH with respect to application serial number 09/977,801. It is therefore submitted that the indicated errors are not connected to the present application.



Patent Application
Attorney Docket No. PC10959AGPR

In case it is helpful, a new copy of the sequence listing is enclosed herewith, along with a new CRF and a statement that the two are identical. It is requested that Applicant receives a corrected document indicating what errors exist in Applicant's Sequence Listing, or a statement that no errors exist at all. If I may be of assistance in this matter, please do not hesitate to call me at the telephone number listed below.

Date:

3/22/02

Respectfully submitted,

A handwritten signature of Gregory P. Raymer in black ink.

Gregory P. Raymer
Attorney for Applicant(s)
Reg. No. 36,647

Pfizer Inc.
Patent Department, MS 4159
Eastern Point Road
Groton, Connecticut 06340
(860) 715-5746

Express Mail No. EL912062466US

03C0



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/023,775	12/18/2001	Mark David Fidock	PC10959AGPR

CONFIRMATION NO. 6589

FORMALITIES LETTER



OC000000007385206

Gregg C. Benson
Pfizer Inc.
Patent Department, MS 4159
Eastern Point Road
Groton, CT 06340

Date Mailed: 01/29/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).


For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY



Patent
Attorney Docket No. PC10959AGPR

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Director - U.S. Patent and Trademark Office, Washington, D.C. 20231 on this 22nd day of March, 2002.

By

Janice M. Denison
(Signature of person mailing)
Janice M. Denison
(Typed or printed name of person)

#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: **Mark David Fidock** :

APPLICATION NO.: **10/023,775** : Examiner: **To be assigned**

FILING DATE: **12/18/2001** : Group Art Unit: **1642**

TITLE: **Novel Polypeptide** :

Box SEQUENCE
Director - U.S. Patent and Trademark Office
Washington, D.C. 20231

STATEMENT REGARDING SUBMISSION
OF SEQUENCE LISTING UNDER 37 C.F.R. §1.821(f)

I hereby state that the information recorded in computer readable form is identical to the written sequence listing.

Date: 3/22/02

Respectfully submitted,

Gregory P. Raymer
Gregory P. Raymer
Attorney for Applicant(s)
Reg. No. 36,347

Pfizer Inc.
Patent Department, MS 4159
Eastern Point Road
Groton, Connecticut 06340
(860) 715-5746